VALARTH See Torrent Pharmaceuticals in the appOpen in app
TORNTPHARM · NSE · Pharmaceuticals

Torrent Pharmaceuticals Ltd

What the numbers mean, from its filings and the exchange. Data as of 12 Oct 2026.
Large Cap · AMFI list Jan-Jun 2026 · Vendor sector: Basic Materials
dear low confidence No valuation within 120 days; P/E 74.3 vs peers 34.9 (13th of 16); P/B 16.9 vs peers 3.7 (15th of 16).
Statements through FY2026Prices adjusted for 2 corporate actionsNot yet reviewed by the adversarial model

What is Torrent Pharmaceuticals's share price today?

Torrent Pharmaceuticals last traded at ₹4,682.00 on the NSE, as of 12 Oct 2026, 11:00 pm IST, up 0.5% on the day, up 32.4% over a year. Its 52-week range is ₹3,481 to ₹5,250. The live price is in the app.

₹4,682.00 +0.5% today
+32.4% over 1 year · NSE, as of 12 Oct 2026, 11:00 pm IST
60 month-end closes, 31 Oct 2021 to 30 Sep 2026, adjusted for splits and bonuses
52-week range68% of the way up
Low ₹3,481High ₹5,250

What is Torrent Pharmaceuticals's market cap?

Torrent Pharmaceuticals's market capitalisation is about ₹1.77 lakh crore: what it would cost to buy every share at today's price. That makes it the 50th largest large cap company we cover.

₹1.8 L Cr Large Cap50th largest large cap company
Large Cap means the 100 largest listed companies, under SEBI's rules. Shares in issue are worked out from the market cap and the price. What market cap tells you →

Key facts

From the exchange
Symbol
NSE: TORNTPHARM
ISIN
INE685A01028
Cap bucket
Large Cap, 50th largest by market cap
Industry (NSE)
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
Listed since
2002
Futures and options
Traded

Is Torrent Pharmaceuticals overvalued?

Dear, with low confidence: no valuation within 120 days; P/E 74.3 vs peers 34.9 (13th of 16); P/B 16.9 vs peers 3.7 (15th of 16).

Valuation

Latest price and trailing 12 months
P/E 74.28
vs peers 34.9 · 13th of 16
Price divided by last year's earnings per share: how many years of today's profit you pay for. Learn more →
P/B 16.90
vs peers 3.7 · 15th of 16
Price divided by book value per share: what you pay for each rupee of net assets on the balance sheet. Learn more →
Market cap ₹1.77 lakh Cr
Total market value of all shares, in ₹ crore. Learn more →
Dividend yield 0.9%
vs peers 0.4% · 4th of 13
Last year's dividends as a share of today's price. Learn more →
PEG (vendor) 20.98
vs peers 2.8 · 11th of 11
P/E divided by the vendor's earnings growth figure, which it does not disclose; a P/E adjusted for how fast profits grow. Learn more →
PEG on our 3-year EPS growth 3.67
P/E divided by the 3-year EPS growth rate from the stored accounts. Learn more →
3 models could be judged
Skipped — Fair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored

Our valuation range

🔒 Pro
Value range, implied growth at today's price, and the nine models behind it: in the app.

Is Torrent Pharmaceuticals a quality business?

Quality score 38.9, 11th of 16 in its peer set; WATCH on 30 of 30 flags judged.

Quality and risk

Data as of 12 Oct 2026
Business quality Not available
The kind of business, which sets the yardstick it is judged by. Learn more →
Quality score 38.9
vs peers 53.3 · 11th of 16
Returns, margins, leverage and consistency against its peers, out of 100. Learn more →
Risk level WATCH
30 of 30 flags judged
From flags on debt, earnings quality, dilution and price swings. Learn more →

Profitability

ROE 27.3%
vs peers 13.3% · 2nd of 16
Return on equity: profit as a share of shareholders' money. Learn more →
ROCE 19.2%
vs peers 14.9% · 5th of 16
Return on capital employed: operating profit as a share of all the capital in the business, debt and equity. Learn more →
Profit margin 13.8%
vs peers 13.8% · 8th of 16
Profit after everything, as a share of revenue. Learn more →
EPS ₹63.17
Trailing 12 months
Profit for each share over the last 12 months.

Scorecard

🔒 Pro
Health scores and red flags with their values and history: in the app.
See the scorecard →
Inside the app

Get a sneak peek of Valarth

Start freeStart free
A Valarth stock page: the share price with its chart and 52-week range, valuation and profitability figures, and a scorecard of health checks.
Stock pagePrice, valuation, profitability and a scorecard of health checks for every company, each figure explained.
The Valarth stock screener: a table of companies with price, market cap, P/E, P/B, PEG, EPS and ROE, and filters down the left.
ScreenerEvery listed company, filtered on 212 figures, each with a plain-language lesson beside it.
The Valarth AI Screener answering 'Which companies will benefit from India's Project 75 submarine programme?' with a basket of four naval shipbuilders and a written thesis.
AI ScreenerAsk a question in plain English, like which companies benefit from India's Project 75. It reads the intent, builds the screen and writes the thesis.
A Valarth business-model card for State Bank of India, with a plain-language summary and statements verified against the filing.
Business modelHow a company makes money and what can hurt it, each statement checked against its annual report.
Valarth's Before the Bell edition, with the day's headline, regulator notes and sector moves.
Before the BellA morning edition before the market opens: what moved, which rule changed, and what it means for your holdings.

Has Torrent Pharmaceuticals made money for shareholders?

Yes: +32.4% over one year and +25.5% a year over five years.

Shareholder returns

1-year return +32.4%
Price only
What the share price did over the last 12 months. Learn more →
5-year return +25.5% a year
Price only
Yearly average price return over five years, bonuses and splits adjusted. Learn more →
Wealth destroyer No
Five-year total return — price CAGR on bonus- and split-adjusted closes plus the dividend yield — below the 7% a bank fixed deposit paid. Learn more →

Returns

3Y and 5Y are yearly averages
1W
−2.4%
1M
−4.0%
3M
−5.9%
6M
+11.4%
1Y
+32.4%
3Y
+35.6%
5Y
+25.5%

Does Torrent Pharmaceuticals pay a dividend?

Yes. Torrent Pharmaceuticals's dividend yield is 0.90% at the latest price; the last payout was ₹9.00 a share, ex-dividend 29 May 2026.

Dividends

Per share, by ex-dividend date
Dividend yield0.90%
The past 12 months' dividends as a share of today's price.
29 May 2026 · Final₹9.00
18 Feb 2026 · Interim₹29.00
20 Jun 2025 · Final₹6.00
31 Jan 2025 · Interim₹26.00
21 Jun 2024 · Final₹6.00
Payout ratio🔒 In the app
The share of profit paid out as dividends; a very high share leaves little to reinvest.
Dividend growth, 5 years🔒 In the app
How fast the dividend per share has grown a year.
Years without a miss🔒 In the app
How many years in a row a dividend has been paid.

Is Torrent Pharmaceuticals growing?

Revenue 3 years 25.7% a year; profit 3 years 20.2% a year; revenue 5 years 12.4% a year.

Growth

Statements through FY2026 (Mar-26)
Revenue 3 years 25.7% a year
vs peers 11.5% · 2nd of 16
Compound annual growth of revenue over three years. Learn more →
Profit 3 years 20.2% a year
vs peers 14.3% · 7th of 16
Compound annual growth of net profit over three years. Learn more →
Revenue 5 years 12.4% a year
Compound annual growth of revenue over five years. Learn more →
Profit 5 years 22.6% a year
Compound annual growth of net profit over five years. Learn more →
EPS 3 years 20.2% a year
Growth in earnings per share, so dilution counts against the company. Learn more →
EPS 5 years 11.6% a year
Growth in earnings per share over five years, so dilution counts against the company. Learn more →
P/E vs own history 15.7%
vs peers 1.5% · 10th of 16
Today's P/E against its own 5-year median; negative is cheaper than its history. Learn more →

How did Torrent Pharmaceuticals do last quarter?

Torrent Pharmaceuticals reported revenue of ₹4,835 Cr, up 67.4% on a year earlier and a net profit of ₹566 Cr, up 11.9% in the Jun 2026 quarter.

Latest quarter

Jun 2026
Revenue, latest quarter₹4,835 Cr
+67.4% on a year earlier
What the company took in over the quarter.
Net profit, latest quarter₹566 Cr
+11.9% on a year earlier
What was left for shareholders after every cost and tax.

How does Torrent Pharmaceuticals compare with its peers?

Compared with 15 Pharmaceuticals; 13th of 16 on P/E; 11th of 16 on quality score.

Compared with 15 Pharmaceuticals

15 companies

Torrent Pharmaceuticals against its peers

Largest 10 of 15 peers, by market cap
CompanyMarket capP/EP/BROEROCE1YQuality 🔒Rank 🔒
Torrent Pharmaceuticals Ltd₹1.8 L Cr74.316.927.3%19.2%+32.4%
Sun Pharmaceutical Industries Ltd₹4.2 L Cr34.918.912.7%14.5%+5.5%
Divis Laboratories Ltd₹2.5 L Cr84.89.416.5%21.4%+42.5%
Zydus Lifesciences Ltd₹1.1 L Cr24.93.715.9%15.9%+12.3%
Laurus Labs Ltd₹1.1 L Cr100.510.215.1%14.9%+132.9%
Cipla Ltd₹1.1 L Cr31.22.910.6%13.9%−16.8%
Dr Reddys Laboratories Ltd₹99,911 Cr30.93.310.7%12.6%−5.2%
Mankind Pharma Ltd₹97,830 Cr47.95.013.3%13.1%−3.0%
Aurobindo Pharma Ltd₹97,411 Cr26.43.311.2%12.9%+48.9%
Lupin Ltd₹89,469 Cr15.83.523.4%27.5%−0.8%
Glenmark Pharmaceuticals Ltd₹64,714 Cr36.02.53.9%6.3%+20.1%
Peer median—34.93.713.3%14.9%+8.9%
Market cap in rupees crore; P/E and P/B on the latest price; 1Y is the price return over a year. A dash is a figure that does not apply or is not reported.

Full peer comparison

🔒 Pro
Every peer, every figure, the ranks and the quality and forensic scores side by side: in the app.

Who owns Torrent Pharmaceuticals?

Torrent Pharmaceuticals is held by promoters 60.8%, foreign institutions 18.0%, domestic institutions 12.9%.

Shareholding pattern

Latest filing, percent of shares
Promoters60.8%
The founders and controlling group.
Foreign institutions18.0%
Overseas funds investing through the FPI route.
Domestic institutions12.9%
Indian insurers, banks, pension and mutual funds together.
Mutual funds8.3%
Indian mutual fund schemes; part of domestic institutions.
Retail and others4.4%
Individual investors and everyone else.
Promoter shares pledged🔒 In the app
Promoter shares given as collateral for loans; a high share is a risk to watch.
Holding trend🔒 In the app
Whether promoters, foreign funds and mutual funds have been adding or selling over recent quarters.

What do analysts say about Torrent Pharmaceuticals?

29 analysts cover Torrent Pharmaceuticals, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

Analyst consensus

29 analysts
ConsensusBuy
The rating most covering analysts give the share.
Average target price🔒 In the app
The mean of the analysts' 12-month price targets.
Upside to target🔒 In the app
How far the target sits above or below today's price.
Share rating it a buy🔒 In the app
The share of covering analysts with a buy rating.

What does Torrent Pharmaceuticals do and what is it sensitive to?

Torrent Pharmaceuticals reports a single segment, Generic Formulation Business, with revenue split by market: India, Germany, United States, Brazil and Others. Sensitive to: brazilian real translation into rupees.

Business-model card

FY2025 · 34 verified
5Revenue
3Channels
3Regulators
3Reg. dependencies
3Sensitivities
3Costs
4Geographies

Torrent Pharmaceuticals reports a single segment, Generic Formulation Business, with revenue split by market: India, Germany, United States, Brazil and Others. Revenue is booked in crores from these markets, with India the largest at Rs 6,393 crores of FY25 revenue against Rs 11,516 crores in total.

Revenue engine

5 verified
Generic Formulation Business (single reported segment)
Sole reported segment. The excerpts give no product-level split, so the revenue lines below are geographic.
India revenue
Largest market line. The FY25 table in chunk 2 shows Rs 6,393 crores of Rs 11,516 crores total.
Germany revenue
Reported market line. The FY25 table in chunk 2 shows Rs 1,139 crores.
2 more statements
United States revenue
Reported market line. The FY25 table in chunk 2 shows Rs 1,100 crores.
Brazil revenue
Reported market line. The FY25 table in chunk 2 shows Rs 1,100 crores.

Customers & channels

3 verified
Medical representative field force (MRs)
Interpretation: the MR force is the company's own sales channel in India. Company states it expanded the force and improved productivity and market share.
Consumer Health Division
Company states it launched this division with a focus on 4 key brands.
Target JB Pharma: CDMO customers
Interpretation: JB Pharma is a proposed merger target, not yet owned. Its CDMO serves other companies, described in the excerpt as leading global consumer healthcare companies.

Regulators

3 verified
National Pharmaceutical Pricing Authority (NPPA)
Governs drug pricing compliance. It raised a 2017 demand alleging overcharging, which the company later settled.
ANVISA
Interpretation: the authority reviewing Torrent's product registrations in Brazil, where it sells.
Competition Commission of India (CCI)
Approval of the proposed JB Pharma merger, conditional on voluntary modifications.

Regulatory dependencies

3 verified
NPPA overcharging demand settled
Interpretation: the price-regulation demand produced an exceptional charge; settlement closed the matter.
Section 115BAA lower tax rate
Company states it will transition to the new tax regime from FY2025-26. Interpretation: the change lowers the tax charge on profit.
Four labour codes effective November 21, 2025
Company states the incremental impact is not material and has been recognised in results. Interpretation: employee cost lines are the exposure.

Sensitivities

3 verified
Brazilian real translation into rupees
Interpretation: reported rupee growth (27%) runs above constant-currency growth (10%), so a weaker real against the rupee lowers reported Rs revenue and a stronger one raises it.
US dollar translation into rupees
Interpretation: reported rupee growth (19%) runs above constant-currency growth (12%), so a weaker dollar against the rupee lowers reported Rs revenue.
Third-party supplier disruption (Germany)
Company states Germany growth was held back by a supply disruption. Interpretation: a supply shortfall lowers the volume sold.

Cost inputs

3 verified
Cost of goods sold, employee benefits and other expenses
Interpretation: these are the operating cost lines in the company's operating margin formula.
Third-party supplier for Germany
Supplier of product whose disruption slowed Germany growth.
JB Pharma acquisition expenses
Expenses incurred for the proposed acquisition, charged to profit and loss, not an operating input.

Geographies

4 verified
India
Largest reported market in the revenue tables.
Germany
Reported market; growth affected by a third-party supplier disruption.
United States
Reported market; growth supported by recent launches.
1 more statement
Brazil
Reported market; products pending ANVISA review.
Each statement is checked word for word against the FY2025 annual report; the passages are in the app.

What changed recently?

Q1 FY2027 results filed (30 Jul 2026).

Change log

8 entries · newest first
  1. Results filedQ1 FY2027 results filed.
  2. Corporate actionDividend - Rs 9 Per Share.
  3. Results filedQ4 FY2026 results filed.
  4. Corporate actionInterim Dividend - Rs 29 Per Share.
  5. Results filedQ3 FY2026 results filed.
  6. Results filedQ2 FY2026 results filed.
  7. Results filedQ1 FY2026 results filed.
  8. Corporate actionDividend - Rs 6 Per Share.
Get alerts →Sign in to be told when any of these change.

What this page does not tell you

What could not be judged, and why. Never empty.
  • Models not runFair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored.
  • FlagsWATCH on 30 of 30 flags judged; 2 red.
  • Data gapsBusiness quality: not available yet.

What this page rests on

✓10 years of annual statements, through FY2026 (Mar-26)✓10 quarters of results✓285 months of month-end prices, adjusted for bonuses and splits (2 corporate actions)○no valuation of ours yet✓business-model card FY2025 · 34 verified

Questions people ask

What is Torrent Pharmaceuticals's share price today?

Torrent Pharmaceuticals last traded at ₹4,682.00 on the NSE, as of 12 Oct 2026, 11:00 pm IST, up 0.5% on the day, up 32.4% over a year. Its 52-week range is ₹3,481 to ₹5,250. The live price is in the app.

What is Torrent Pharmaceuticals's market cap?

Torrent Pharmaceuticals's market capitalisation is about ₹1.77 lakh crore: what it would cost to buy every share at today's price. That makes it the 50th largest large cap company we cover.

Is Torrent Pharmaceuticals Ltd a large cap, mid cap or small cap?

Torrent Pharmaceuticals Ltd (TORNTPHARM) is a large cap company in AMFI's classification for Jan-Jun 2026. SEBI's buckets go by rank on six-month average market capitalisation: the top 100 are large caps, 101 to 250 mid caps, the rest small caps.

What is Torrent Pharmaceuticals Ltd's P/E ratio?

74.28, vs peers 34.9 · 13th of 16. Price divided by last year's earnings per share: how many years of today's profit you pay for.

Is Torrent Pharmaceuticals Ltd overvalued?

Dear, with low confidence: no valuation within 120 days; P/E 74.3 vs peers 34.9 (13th of 16); P/B 16.9 vs peers 3.7 (15th of 16).

How does Torrent Pharmaceuticals Ltd make money?

Torrent Pharmaceuticals reports a single segment, Generic Formulation Business, with revenue split by market: India, Germany, United States, Brazil and Others. Revenue is booked in crores from these markets, with India the largest at Rs 6,393 crores of FY25 revenue against Rs 11,516 crores in total.

Who are Torrent Pharmaceuticals Ltd's peers?

Compared with 15 Pharmaceuticals: Sun Pharmaceutical Industries Ltd, Divis Laboratories Ltd, Zydus Lifesciences Ltd, Laurus Labs Ltd, Cipla Ltd and 10 more. The app shows how they compare on every figure.

Is this investment advice?

No. Valarth is a research and learning tool and is not a SEBI-registered investment adviser or research analyst. The figures come from the company's filings and the exchanges; what to do with them is your call.

How did Torrent Pharmaceuticals do last quarter?

Torrent Pharmaceuticals reported revenue of ₹4,835 Cr, up 67.4% on a year earlier and a net profit of ₹566 Cr, up 11.9% in the Jun 2026 quarter.

Who owns Torrent Pharmaceuticals?

Torrent Pharmaceuticals is held by promoters 60.8%, foreign institutions 18.0%, domestic institutions 12.9%.

Does Torrent Pharmaceuticals pay a dividend?

Yes. Torrent Pharmaceuticals's dividend yield is 0.90% at the latest price; the last payout was ₹9.00 a share, ex-dividend 29 May 2026.

What do analysts say about Torrent Pharmaceuticals?

29 analysts cover Torrent Pharmaceuticals, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

Everything on Torrent Pharmaceuticals, and 6,621 other companies, with 212 filters and the full peer tables

See Torrent Pharmaceuticals in the app →See pricing